Advertisement

Diagnosis of Limited Cancer in Prostate Biopsy

  • Rajal B. ShahEmail author
  • Ming Zhou
Chapter

Abstract

In the last decade, there has been significant shift in the objectives of prostate cancer screening, diagnosis, and management, from diagnosing and treating all cancers to clinically significant ones. New and recently emerged tools, such as magnetic resonance imaging (MRI) and molecular and genomic tests, are potentially useful in distinguishing life-threatening from low-risk, indolent tumors. However, currently there are no tests that are 100% accurate in predicting which patients may have clinically significant disease. Prostate needle biopsy is still the gold standard to establish a cancer diagnosis, and pathologists still need to evaluate prostate biopsies with due diligence and diagnose all cancers that meet the accepted diagnostic criteria.

Diagnosis of cancer in prostate biopsy is often challenging, especially when the cancer focus is minute. There are two main issues: (1) recognition of limited cancer to avoid underdiagnosis (false-negative) and (2) recognition of benign mimics of prostate cancer to avoid overdiagnosis (false-positive). Diagnosis of cancer in prostate needle biopsy requires a methodical approach using a constellation of architectural and cytological features of cancer glands and sometimes also requires ancillary immunohistochemistry. However, no two pathologists have the same threshold for diagnosing limited cancer in biopsy, and even one’s own threshold changes with time and experience. It is therefore expected that pathologists may not always agree upon a diagnosis in some borderline cases. It is critical, however, to recognize these cases as being atypical and suspicious for cancer so that further workup will ensue. In this sense, the most critical issue in prostate biopsy interpretation is to identify prostate glands that are morphologically atypical and suspicious for cancer.

Keywords

Prostate needle biopsy Limited cancer Prostate cancer diagnosis Mucinous fibroplasia (collagenous micronodules) Glomerulation Perineural invasion Major diagnostic feature Minor diagnostic feature Abnormal architectural pattern Infiltrative growth Crowded growth Cribriform Solid nests Single cell Absence of basal cells Nuclear atypia Hyperchromasia Prominent nucleoli Nuclear enlargement Amphophilic cytoplasm Crystalloids Blue mucin Intraluminal amorphous secretion Mitosis Apoptosis Periacinar/glandular clefting Quantitative threshold Benign lesions Mimicking cancer Atypical glands suspicious for cancer (ATYP) Immunohistochemistry 

References

  1. 1.
    Magi-Galluzzi C. Prostate cancer: diagnostic criteria and role of immunohistochemistry. Mod Pathol. 2018;31(S1):S12–21.CrossRefGoogle Scholar
  2. 2.
    Humphrey PA. Diagnosis of adenocarcinoma in prostate needle biopsy tissue. J Clin Pathol. 2007;60:35–42.CrossRefGoogle Scholar
  3. 3.
    Baisden BL, Kahane H, Epstein JI. Perineural invasion, mucinous fibroplasia, and glomerulations: diagnostic features of limited cancer on prostate needle biopsy. Am J Surg Pathol. 1999;23:918–24.CrossRefGoogle Scholar
  4. 4.
    Thorson P, Vollmer RT, Arcangeli C, Keetch DW, Humphrey PA. Minimal carcinoma in prostate needle biopsy specimens: diagnostic features and radical prostatectomy follow-up. Mod Pathol. 1998;11:543–51.PubMedGoogle Scholar
  5. 5.
    Pacelli A, Lopez-Beltran A, Egan AJM, Bostwick DG. Prostate adenocarcinoma with glomeruloid features. Hum Pathol. 1998;29:543–6.CrossRefGoogle Scholar
  6. 6.
    Humphrey PA. Prostate pathology. Chicago: American Journal of Clinical Pathology Press; 2003.Google Scholar
  7. 7.
    Algaba F, Epstein JI, Aldape HC, Farrow GM, Lopez-Beltran A, Maksem J, et al. Assessment of prostate carcinoma in core needle biopsy – definition of minimal criteria for the diagnosis of cancer in biopsy material. Cancer. 1996;78:376–81.CrossRefGoogle Scholar
  8. 8.
    Totten RS, Heinemann MW, Hudson PB, Sproul EE, Stout AP. Microscopic differential diagnosis of latent carcinoma of prostate. AMA Arch Pathol. 1953;55:131–41.PubMedGoogle Scholar
  9. 9.
    Cleary KR, Choi HY, Ayala AG. Basal cell hyperplasia of the prostate. Am J Clin Pathol. 1983;80:850–4.CrossRefGoogle Scholar
  10. 10.
    Devaraj LT, Bostwick DG. Atypical basal cell hyperplasia of the prostate. Immunophenotypic profile and proposed classification of basal cell proliferations. Am J Surg Pathol. 1993;17:645–59.CrossRefGoogle Scholar
  11. 11.
    Aydin H, Zhou M, Herawi M, Epstein JI. Number and location of nucleoli and presence of apoptotic bodies in diagnostically challenging cases of prostate adenocarcinoma on needle biopsy. Hum Pathol. 2005;36:1172–7.CrossRefGoogle Scholar
  12. 12.
    Helpap B. Observations on the number, size and localization of nucleoli in hyperplastic and neoplastic prostatic disease. Histopathology. 1988;13:203–11.CrossRefGoogle Scholar
  13. 13.
    Varma M, Lee MW, Tamboli P, Zarbo RJ, Jimenez RE, Salles PG, et al. Morphologic criteria for the diagnosis of prostatic adenocarcinoma in needle biopsy specimens. A study of 250 consecutive cases in a routine surgical pathology practice. Arch Pathol Lab Med. 2002;126:554–61.PubMedGoogle Scholar
  14. 14.
    Epstein JI. Diagnostic criteria of limited adenocarcinoma of the prostate on needle biopsy. Hum Pathol. 1995;26:223–9.CrossRefGoogle Scholar
  15. 15.
    Epstein JI, Fynheer J. Acidic mucin in the prostate: can it differentiate adenosis from adenocarcinoma? Hum Pathol. 1992;23:1321–5.CrossRefGoogle Scholar
  16. 16.
    Henneberry JM, Kahane H, Humphrey PA, Keetch DW, Epstein JI. The significance of intraluminal crystalloids in benign prostatic glands on needle biopsy. Am J Surg Pathol. 1997;21:725–8.CrossRefGoogle Scholar
  17. 17.
    Ro JY, Ayala AG, Ordonez NG, Cartwright J Jr, Mackay B. Intraluminal crystalloids in prostatic adenocarcinoma. Immunohistochemical, electron microscopic, and x-ray microanalytic studies. Cancer. 1986;57:2397–407.CrossRefGoogle Scholar
  18. 18.
    Vesalainen S, Lipponen P, Talja M, Syrjanen K. Mitotic activity and prognosis in prostatic adenocarcinoma. Prostate. 1995;26:80–6.CrossRefGoogle Scholar
  19. 19.
    Ulamec M, Tomas D, Ensinger C, et al. Periacinar retraction clefting in proliferative prostatic atrophy and prostatic adenocarcinoma. J Clin Pathol. 2007;60:1098–101.CrossRefGoogle Scholar
  20. 20.
    Amin MB, Tamboli P, Varma M, Srigley JR. Postatrophic hyperplasia of the prostate gland: a detailed analysis of its morphology in needle biopsy specimens. Am J Surg Pathol. 1999;23:925–31.CrossRefGoogle Scholar
  21. 21.
    Bostwick DG, Srigley J, Grignon D, Maksem J, Humphrey P, van der Kwast TH, et al. Atypical adenomatous hyperplasia of the prostate: morphologic criteria for its distinction from well-differentiated carcinoma. Hum Pathol. 1993;24:819–32.CrossRefGoogle Scholar
  22. 22.
    Gaudin PB, Epstein JI. Adenosis of the prostate. Histologic features in needle biopsy specimens. Am J Surg Pathol. 1995;19:737–47.CrossRefGoogle Scholar
  23. 23.
    Kronz JD, Shaikh AA, Epstein JI. High-grade prostatic intraepithelial neoplasia with adjacent small atypical glands on prostate biopsy. Hum Pathol. 2001;32:389–95.CrossRefGoogle Scholar
  24. 24.
    Iczkowski KA, Bostwick DG. Criteria for biopsy diagnosis of minimal volume prostatic adenocarcinoma: analytic comparison with nondiagnostic but suspicious atypical small acinar proliferation. Arch Pathol Lab Med. 2000;124:98–107.PubMedGoogle Scholar
  25. 25.
    Epstein JI, Netto GJ. Diagnosis of limited adenocarcinoma of the prostate. In: Biopsy interpretation of the prostate. Philadelphia: Lippincott Williams and Wilkins; 2014.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Robert J Tomsich Pathology and Laboratory Medicine InstituteCleveland ClinicClevelandUSA
  2. 2.Tufts Medical CenterBostonUSA

Personalised recommendations